ES2606546T3 - Compuesto destinado a la absorción bucal de nicotina con el objetivo de dejar de fumar - Google Patents
Compuesto destinado a la absorción bucal de nicotina con el objetivo de dejar de fumar Download PDFInfo
- Publication number
- ES2606546T3 ES2606546T3 ES10721627.7T ES10721627T ES2606546T3 ES 2606546 T3 ES2606546 T3 ES 2606546T3 ES 10721627 T ES10721627 T ES 10721627T ES 2606546 T3 ES2606546 T3 ES 2606546T3
- Authority
- ES
- Spain
- Prior art keywords
- weight
- concentration
- nicotine
- group
- flavanones
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Addiction (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
El compuesto destinado a la aplicación bucal de nicotina al sistema circulatorio y a la distribución al sistema nervioso central, aplicable en forma coloidal o en forma de un dispositivo atomizador con el fin de dejar de fumar o de su sustitución en el caso de ser las condiciones para fumar desfavorables. De conformidad con la invención en referencia, el compuesto se destaca por el hecho, de que contiene una solución de nicotina en forma de base y/o de sus sales con un ácido orgánico en una concentración de 0,10 a 4,00% del peso, la concentración más apropiada es de 0,20 a 1,00% del peso. Además contiene materias que tienen efecto mucolítico del grupo de acetilcisteina en una concentración de 3,00 a 30,0% del peso y/o fitocomplejos que poseen efecto mucolítico, adquiridos mediante la extracción de las plantas seleccionadas del grupo Primula veris, Primula elatior, Hedera helix, Eucalyptus globulus nebo Liquiritia glabra en una concentración de0,50 a 15,00% del peso de fitocomplejo con un efecto antioxidante seleccionado del grupo de flavonas, flavonoles, flavanones flavanonoles, isoflavonas, neoflavonoides, antocianidinas, pro-antociadinas y de sus oligómeros y polímeros, adquiridos mediante la extracción de las plantas Camellia sinensis, Curcuma longa, Rosmarinus officinalis, Sylibium marianum, Vitis vinifera, Ginkgo biloba, Euterpe oleracea, Vaccinium myrtillus, Morinda citrifolia, Malpighia glabra, las cuales contienen además un retardador (amortiguador) que modifica la acidez a un rango de pH de 7,0 a 9,0.
Description
Ejemplos 1, 2 y 3:
- Componente:
- Composición (% del peso)
- Muestra nro.. 1
- Muestra nro. 2 Muestra nro. 3
- Nicotina
- 1,00 2,00 3,00
- Ácido cítrico
- 0,95 1,55 2,10
- Acetilcisteina
- 25,00 15,00 5,00
- Ascorbil fosfato de sodio
- 3,00 5,00
- Sorbato de potasio
- 0,10 0,10 0,10
- Benzoato de sodio
- 0,10 0,10 0,10
- Sucralosa
- 0,07 0,08 0,10
- Glicerina
- 5,00 10,00 15,00
- Grape seeda extrakt
- 1,50 0,75
- Perfume
- 0,10 0,20 0,35
- Aceite de ricina hidrogenado pegilado
- 0,12 0,12 0,12
- Hidróxido de sodio
- q.s. pH 7,0 - 9,0 q.s. pH 7,0 - 9,0 q.s. pH 7,0 - 9,0
- Agua
- do 100,00g do 100,00g do 100,00g
Procedimiento de preparación: en el agua se disuelven componentes que se agregan individualmente de manera
5 paulatina. La solución se filtra según sea necesario y se vierte en recipientes de presión, dotados de una válvula dosificadora o en recipientes cerrados provistos de una válvula dosificadora, impulsada por una bomba de accionamiento manual.
De conformidad con la invención, el compuesto puede ser fabricado por la industria farmacéutica. El preparado 10 resulta apropiado para la absorción transmucosa de nicotina con el objetivo de dejar de fumar.
6
Claims (1)
-
imagen1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CZ20090080 | 2009-02-11 | ||
CZ20090080A CZ200980A3 (cs) | 2009-02-11 | 2009-02-11 | Kompozice urcená k bukální absorpci nikotinu za úcelem odvykání kourení |
CZ20090829 | 2009-12-09 | ||
CZ2009829 | 2009-12-09 | ||
PCT/CZ2010/000011 WO2010091649A2 (en) | 2009-02-11 | 2010-02-03 | A composition for buccal absorption of nicotine for the purpose of smoking cessation |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2606546T3 true ES2606546T3 (es) | 2017-03-24 |
Family
ID=69162740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10721627.7T Active ES2606546T3 (es) | 2009-02-11 | 2010-02-03 | Compuesto destinado a la absorción bucal de nicotina con el objetivo de dejar de fumar |
Country Status (14)
Country | Link |
---|---|
US (2) | US20110293535A1 (es) |
EP (1) | EP2395974B1 (es) |
JP (1) | JP2012517402A (es) |
KR (1) | KR20110114552A (es) |
CN (1) | CN102316850A (es) |
AU (1) | AU2010213244A1 (es) |
CA (1) | CA2751271A1 (es) |
EA (1) | EA201100896A1 (es) |
ES (1) | ES2606546T3 (es) |
IL (1) | IL212720A (es) |
PT (1) | PT2395974T (es) |
SG (1) | SG171870A1 (es) |
WO (1) | WO2010091649A2 (es) |
ZA (1) | ZA201103096B (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10244793B2 (en) | 2005-07-19 | 2019-04-02 | Juul Labs, Inc. | Devices for vaporization of a substance |
US20140166027A1 (en) * | 2012-12-14 | 2014-06-19 | Richard C. Fuisz | Enhanced Delivery of Nicotine, THC, Tobacco, Cannabidiol or Base Alkaloid from an Electronic Cigarette or Other Vapor Producing Device Through Use of an Absorption Conditioning Unit |
US20140166028A1 (en) * | 2012-12-14 | 2014-06-19 | Richard C. Fuisz | Enhanced Delivery of Nicotine, THC, Tobacco, Cannabidiol or Base Alkaloid from an Electronic Cigarette or Other Vapor or Smoke Producing Device Through Use of an Absorption Conditioning Unit |
US10638792B2 (en) | 2013-03-15 | 2020-05-05 | Juul Labs, Inc. | Securely attaching cartridges for vaporizer devices |
IL297399B2 (en) * | 2013-05-06 | 2024-02-01 | Juul Labs Inc | Nicotine salt formulations for aerosol devices and methods thereof |
CA2913489C (en) * | 2013-06-07 | 2019-04-30 | Remi Shrivastava | Composition for topical application comprising glycerol and tannins |
US10463069B2 (en) * | 2013-12-05 | 2019-11-05 | Juul Labs, Inc. | Nicotine liquid formulations for aerosol devices and methods thereof |
US10076139B2 (en) | 2013-12-23 | 2018-09-18 | Juul Labs, Inc. | Vaporizer apparatus |
US20160366947A1 (en) | 2013-12-23 | 2016-12-22 | James Monsees | Vaporizer apparatus |
CN110664012A (zh) | 2013-12-23 | 2020-01-10 | 尤尔实验室有限公司 | 蒸发装置系统和方法 |
US10159282B2 (en) | 2013-12-23 | 2018-12-25 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
US10058129B2 (en) | 2013-12-23 | 2018-08-28 | Juul Labs, Inc. | Vaporization device systems and methods |
USD842536S1 (en) | 2016-07-28 | 2019-03-05 | Juul Labs, Inc. | Vaporizer cartridge |
USD825102S1 (en) | 2016-07-28 | 2018-08-07 | Juul Labs, Inc. | Vaporizer device with cartridge |
CN107427067B (zh) | 2014-12-05 | 2020-10-23 | 尤尔实验室有限公司 | 校正剂量控制 |
CN104770864B (zh) * | 2015-02-13 | 2016-08-24 | 华健 | 一种清热润喉的电子雾化液及其制备方法 |
WO2016133890A1 (en) * | 2015-02-19 | 2016-08-25 | Srq Patent Holdings, Llc | Compositions for e-cigarettes |
GB201516729D0 (en) * | 2015-09-22 | 2015-11-04 | The Technology Partnership Plc | Liquid nicotine formulation |
CA2914089C (en) | 2015-12-03 | 2018-12-18 | Euro-Pharm International Canada Inc. | Nicotine-containing liquid formulations and uses thereof |
US10405582B2 (en) | 2016-03-10 | 2019-09-10 | Pax Labs, Inc. | Vaporization device with lip sensing |
USD849996S1 (en) | 2016-06-16 | 2019-05-28 | Pax Labs, Inc. | Vaporizer cartridge |
USD851830S1 (en) | 2016-06-23 | 2019-06-18 | Pax Labs, Inc. | Combined vaporizer tamp and pick tool |
USD836541S1 (en) | 2016-06-23 | 2018-12-25 | Pax Labs, Inc. | Charging device |
USD887632S1 (en) | 2017-09-14 | 2020-06-16 | Pax Labs, Inc. | Vaporizer cartridge |
KR20210119488A (ko) * | 2019-01-25 | 2021-10-05 | 차이나 토바코 후난 인더스트리얼 코포레이션 리미티드 | 수계 전자 담배 액체 |
CN111000283A (zh) * | 2019-12-13 | 2020-04-14 | 武汉红金叶新材料科技有限公司 | 一种用于气溶胶装置的电子烟油及其制备方法和应用 |
SE546142C2 (en) * | 2020-04-03 | 2024-06-11 | Liw Innovation Ab | New compositions for oral use |
JP2024519516A (ja) * | 2021-04-23 | 2024-05-15 | トーマス メネギニ | 消毒剤及びその使用 |
CN116649576B (zh) * | 2023-06-14 | 2024-10-29 | 深圳市吉迩科技有限公司 | 一种含有抑菌抗氧化组合物的尼古丁口含制品及其制备方法 |
CN117099995A (zh) * | 2023-09-05 | 2023-11-24 | 东莞市吉纯生物技术有限公司 | 一种抗氧化电子雾化液及其制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63196524A (ja) * | 1987-02-10 | 1988-08-15 | Wakunaga Pharmaceut Co Ltd | 経粘膜吸収型制ガン作用調節剤 |
IT1265312B1 (it) * | 1993-12-21 | 1996-10-31 | Indena Spa | Formulazioni contenenti carotenoidi e procarotenoidi associati a polifenoli nella prevenzione dei danni da abnorme produzione di |
PT910339E (pt) * | 1996-04-12 | 2005-05-31 | Novadel Pharma Inc | Aerossol polar bucal |
US20080138399A1 (en) * | 1999-07-16 | 2008-06-12 | Aradigm Corporation | Dual release nicotine formulations, and systems and methods for their use |
US6277855B1 (en) * | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
US20040002520A1 (en) * | 2002-07-01 | 2004-01-01 | Soderlund Patrick L. | Composition and method for cessation of Nicotine cravings |
US7244709B2 (en) * | 2004-05-10 | 2007-07-17 | Nastech Pharamecutical Company Inc. | Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
EP2526943B1 (en) * | 2006-02-13 | 2017-03-22 | Orient Pharma (Samoa) Co, Ltd | Liquid formulation comprising an alpha-2 receptor agonist (e.g. clonidin) and oxybutynin (anti-muscarinic agent) for the treatment of sialorrhoea |
WO2008069970A2 (en) * | 2006-12-01 | 2008-06-12 | Aradigm Corporation | Nicotine formulations, kits and systems and methods for their use |
US20080286340A1 (en) * | 2007-05-16 | 2008-11-20 | Sven-Borje Andersson | Buffered nicotine containing products |
GB0712308D0 (en) * | 2007-06-25 | 2007-08-01 | Kind Group Ltd | An inhalable composition |
-
2010
- 2010-02-03 ES ES10721627.7T patent/ES2606546T3/es active Active
- 2010-02-03 SG SG2011039500A patent/SG171870A1/en unknown
- 2010-02-03 PT PT107216277T patent/PT2395974T/pt unknown
- 2010-02-03 CN CN2010800073110A patent/CN102316850A/zh active Pending
- 2010-02-03 AU AU2010213244A patent/AU2010213244A1/en not_active Abandoned
- 2010-02-03 EA EA201100896A patent/EA201100896A1/ru unknown
- 2010-02-03 CA CA2751271A patent/CA2751271A1/en not_active Abandoned
- 2010-02-03 US US13/147,597 patent/US20110293535A1/en not_active Abandoned
- 2010-02-03 KR KR1020117015113A patent/KR20110114552A/ko not_active Application Discontinuation
- 2010-02-03 EP EP10721627.7A patent/EP2395974B1/en active Active
- 2010-02-03 WO PCT/CZ2010/000011 patent/WO2010091649A2/en active Application Filing
- 2010-02-03 JP JP2011548524A patent/JP2012517402A/ja active Pending
-
2011
- 2011-04-28 ZA ZA2011/03096A patent/ZA201103096B/en unknown
- 2011-05-05 IL IL212720A patent/IL212720A/en active IP Right Grant
-
2019
- 2019-09-07 US US16/563,824 patent/US20200022905A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2012517402A (ja) | 2012-08-02 |
EP2395974A2 (en) | 2011-12-21 |
CA2751271A1 (en) | 2010-08-19 |
WO2010091649A4 (en) | 2010-12-29 |
KR20110114552A (ko) | 2011-10-19 |
SG171870A1 (en) | 2011-07-28 |
IL212720A (en) | 2016-02-29 |
WO2010091649A3 (en) | 2010-11-11 |
AU2010213244A1 (en) | 2010-08-19 |
WO2010091649A2 (en) | 2010-08-19 |
PT2395974T (pt) | 2016-12-14 |
EP2395974B1 (en) | 2016-09-07 |
IL212720A0 (en) | 2011-07-31 |
US20200022905A1 (en) | 2020-01-23 |
ZA201103096B (en) | 2011-12-28 |
CN102316850A (zh) | 2012-01-11 |
EA201100896A1 (ru) | 2012-01-30 |
US20110293535A1 (en) | 2011-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2606546T3 (es) | Compuesto destinado a la absorción bucal de nicotina con el objetivo de dejar de fumar | |
Zhu et al. | Prophylactic effects of quercetin and hyperoside in a calcium oxalate stone forming rat model | |
AR113749A1 (es) | Formulaciones cannabinoides sintéticas y a base de plantas de inicio rápido y acción prolongada | |
BRPI0710485B1 (pt) | composições líquidas úteis no tratamento de doenças respiratórias | |
AR078812A1 (es) | Preparacion que comprende aminoacidos y plantas y su actividad en la detoxificacion del alcohol | |
ES2488407T3 (es) | Preparación farmacéutica que contiene lipasa de origen bacteriano | |
RU2011138101A (ru) | Фармацевтическая композиция, проявляющая противовоспалительные свойства | |
US11446232B2 (en) | Natural skin penetrating moisturizer formulations | |
ES2720954T3 (es) | Formulaciones estabilizadas de estatina | |
CL2009000309A1 (es) | Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2. | |
CY1111369T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολη και παρακεταμολη | |
ES2606141T3 (es) | Composiciones para el tratamiento de úlceras periféricas de diversos orígenes | |
WO2022162711A1 (en) | Composition for the treatment of painful and/or inflammatory states | |
CL2014000035A1 (es) | Composicion en forma de un gel para la preparacion de un producto alimenticio, que comprende agua en una cantidad de 30 a 70% en peso, saborizantes desde 1 a 40%, sal desde 10 a 25% y agentes gelificantes desde 0,15 a 12% que contienen al menos agar y xantano; y proceso para preparar dicha composicion. | |
HRP20140215T1 (hr) | Kombinacija koja sadrži paklitaksel za lijeäśenje raka jajnika | |
Alibasyah et al. | potensi antibakteri ekstrak jahe (Zingiber officinale Roscoe) terhadap Porphyromonas gingivalis secara in vitro | |
ES2624593T3 (es) | Sal de hidrobromuro de un compuesto anti-VIH. | |
BRPI1014412A8 (pt) | Nanocápsulas de poliarginina | |
CL2007000485A1 (es) | Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina. | |
Gupta et al. | Comparison of antimicrobial activities of clove oil and its extract on some food borne microbes | |
UY32600A (es) | Formulación en lípidos de un promotor de la apoptosis | |
CN103585660A (zh) | 一种新型空气清新剂 | |
BR112014030288A2 (pt) | composição farmacêutica | |
RU2013137782A (ru) | Водный ионный раствор, содержащий морскую воду, по меньшей мере одно соединение, изначально не смешивающееся с морской водой | |
FR2938766B1 (fr) | Composition cosmetique et/ou pharmaceutique comprenant un hydrolysat de feuille de vigne (vitis vinifera l.) en tant que principe actif activateur de l'aconitase et protecteur des mitochondries |